Cargando…
Use of vedolizumab in a patient with chronic and refractory pouchitis
Autores principales: | Orfanoudaki, Eleni, Foteinogiannopoulou, Kalliopi, Koutroubakis, Ioannis E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hellenic Society of Gastroenterology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5924862/ https://www.ncbi.nlm.nih.gov/pubmed/29720865 http://dx.doi.org/10.20524/aog.2018.0243 |
Ejemplares similares
-
Pyoderma gangrenosum associated with chronic refractory pouchitis: a case successfully treated with infliximab
por: Koumaki, Dimitra, et al.
Publicado: (2020) -
Vedolizumab for chronic antibiotic-refractory pouchitis
por: Singh, Amandeep, et al.
Publicado: (2019) -
Keeping on the High Quality of Health Care in Greek Inflammatory Bowel Disease Patients in the SARS-CoV-2 Era
por: Foteinogiannopoulou, Kalliopi, et al.
Publicado: (2020) -
Recent Advances in the Optimization of Anti-TNF Treatment in Patients with Inflammatory Bowel Disease
por: Orfanoudaki, Eleni, et al.
Publicado: (2023) -
Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
por: Theodoraki, Eirini, et al.
Publicado: (2021)